Kimberly-Clark Corp (KMB) has been experiencing some considerable activities both in market performance and corporate actions. Amid fluctuating stock performance compared to competitors, the company remains a favorite among institutional investors who own 79% of its shares. Recent transactions by QRG Capital Management Inc., Manning & Napier Advisors LLC, and Janus Henderson Group PLC added an aggregate of over 900 shares, albeit modest insider selling by top executives, including President of Latin America Gonzalo Uribe, Vice President and Controller Andrew Drexler, and Chief Business & Transformation Officer Jeffrey Melucci. Despite weaker tissue demand impacting earnings, Kimberly-Clark exceeded second-quarter earnings estimates, raising its 2024 outlook twice. New appointments have been made with Craig Slavtcheff named Chief Research and Development Officer, and Patricia Corsi as Chief Growth Officer. The firm further reported solid organic growth and cost recovery in 2023, and its strategy focusing on its core business is said to be driving growth. However, the company is exiting Africa's largest market and recently sold its PPE business for $640M. A dividend increase was declared despite mixed results, with the company perceived as using its debt sensibly. The company continues to invest in strategic transformation, unveiling a new operating model and setting long-term financial targets.
Kimberly-Clark Corp KMB News Analytics from Tue, 24 Oct 2023 07:00:00 GMT to Sun, 11 Aug 2024 16:35:40 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -3
